French recommendations for malignant pheochromocytomas and paragangliomas by the national ENDOCAN-COMETE network

Bull Cancer. 2023 Aug 10:S0007-4551(23)00297-7. doi: 10.1016/j.bulcan.2023.06.002. Online ahead of print.ABSTRACTPheochromocytomas and paragangliomas are rare neuroendocrine tumors, developed respectively in the adrenal medulla and in extra-adrenal locations. Their malignancy is defined by the presence of distant metastases. Forty percent of them are inherited and can be part of different hereditary syndromes. Their management is ensured in France by the multidisciplinary expert centers of the ENDOCAN-COMETE national network "Cancers of the Adrenal gland", certified by the National Cancer Institute and discussed within multidisciplinary team meetings. The diagnostic and therapeutic work-up must be standardized, based on an expert analysis of clinical symptoms, hormonal biological secretions, genetics, morphological and specific metabolic imaging. In the context of a heterogeneous survival sometimes beyond seven to ten years, therapeutic intervention must be justified. This is multidisciplinary and relies on surgery, interventional radiology, external or internal radiotherapy and medical treatments such as sunitinib or dacarbazine and temodal chemotherapy. The personalized approach based on functional imaging fixation status and genetics is progressing despite the extreme rarity of this disease.PMID:37573200 | DOI:10.1016/j.bulcan.2023.06.002
Source: Bulletin du Cancer - Category: Cancer & Oncology Authors: Source Type: research